About Forte Biosciences
Forte Biosciences is a company based in Torrance (United States) founded in 2017 by Paul A. Wagner. The company has 14 employees as of December 31, 2024. Forte Biosciences operates in a competitive market with competitors including ASLAN Pharmaceuticals, Concerto Biosciences, UNION Therapeutics, Biosion and PinCell, among others.
- Headquarter Torrance, United States
- Employees 14 as on 31 Dec, 2024
- Founders Paul A. Wagner
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Forte Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$35.48 M (USD)-12.71as on Dec 31, 2024
-
EBITDA
-$36.56 M (USD)-12.58as on Dec 31, 2024
-
Latest Funding Round
$37.86 M (USD), Post-IPO
Nov 20, 2024
-
Investors
Orbimed
& 6 more
-
Employee Count
14
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Forte Biosciences
Forte Biosciences is a publicly listed company on the NASDAQ with ticker symbol FBRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Forte Biosciences
Unlock access to complete
Funding Insights of Forte Biosciences
Investors in Forte Biosciences
Forte Biosciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Janus Henderson Investors and Alger.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
ESG investments are managed by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Forte Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Forte Biosciences
Investment portfolio details for Forte Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Forte Biosciences
Detailed financials for Forte Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Forte Biosciences Comparisons
Peer comparison for Forte Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Forte Biosciences
Forte Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ASLAN Pharmaceuticals, Concerto Biosciences, UNION Therapeutics, Biosion and PinCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted small molecules are developed for oncology treatments.
|
|
| Locked | Locked | Locked |
Microbe-based products are developed for agriculture and human health.
|
|
| Locked | Locked | Locked |
Small molecule antibiotics are developed for bacterial infections.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Developer of anti-inflammatory therapy for the treatment skin diseases
|
Detailed competitors of Forte Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Forte Biosciences
Complete news archive for Forte Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Forte Biosciences
Forte Biosciences was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Forte Biosciences is headquartered in Torrance, United States. It is registered at Torrance, California, United States.
Paul A. Wagner is the current CEO of Forte Biosciences. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Forte Biosciences is 14.
Forte Biosciences was founded in 2017 and is based in Torrance, United States. Operations focus on the biotechnology sector, where therapeutic solutions for inflammatory skin diseases are developed. The lead product, FB-401, is a topical formulation derived from strains of the commensal gram-negative bacteria Roseomonas mucosa. This approach targets treatment of conditions such as atopic dermatitis through microbial-based therapies.
Forte Biosciences's top competitors include ASLAN Pharmaceuticals, Concerto Biosciences and UNION Therapeutics.
Yes, Forte Biosciences is publicly traded on NASDAQ under the ticker symbol FBRX.
Forte Biosciences has 7 investors. Key investors include Orbimed, Janus Henderson Investors, Alger, Tybourne Capital Management, and Ikarian Capital.
The ticker symbol of Forte Biosciences is FBRX on NASDAQ.